Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Long-term risk of secondary skin cancers after radiation therapy for Hodgkin's lymphoma.

Daniëls LA, Krol AD, Schaapveld M, Putter H, Jansen PM, Marijt EW, van Leeuwen FE, Creutzberg CL.

Radiother Oncol. 2013 Oct;109(1):140-5. doi: 10.1016/j.radonc.2013.06.041. Epub 2013 Aug 7.

PMID:
23932152
2.

Incidence of second cancers in patients treated for Hodgkin's disease.

Boivin JF, Hutchison GB, Zauber AG, Bernstein L, Davis FG, Michel RP, Zanke B, Tan CT, Fuller LM, Mauch P, et al.

J Natl Cancer Inst. 1995 May 17;87(10):732-41.

PMID:
7563150
3.

Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes.

De Bruin ML, Sparidans J, van't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2009 Sep 10;27(26):4239-46. doi: 10.1200/JCO.2008.19.9174. Epub 2009 Aug 10.

PMID:
19667275
4.

Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.

Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canellos GP, Tarbell NJ.

Blood. 1996 May 1;87(9):3625-32.

5.

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE.

N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949.

6.

Breast cancer after treatment of Hodgkin's disease.

Hancock SL, Tucker MA, Hoppe RT.

J Natl Cancer Inst. 1993 Jan 6;85(1):25-31.

PMID:
8416252
7.

Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.

Swerdlow AJ, Barber JA, Horwich A, Cunningham D, Milan S, Omar RZ.

Br J Cancer. 1997;75(1):116-23.

8.

Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group.

Karagas MR, McDonald JA, Greenberg ER, Stukel TA, Weiss JE, Baron JA, Stevens MM.

J Natl Cancer Inst. 1996 Dec 18;88(24):1848-53.

PMID:
8961975
9.

Second cancer among long-term survivors from Hodgkin's disease.

Nyandoto P, Muhonen T, Joensuu H.

Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):373-8.

PMID:
9788418
10.

Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.

Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R, van der Graaf WT, Coebergh JW, van Leeuwen FE.

J Clin Oncol. 2008 Mar 10;26(8):1239-46. doi: 10.1200/JCO.2007.11.9081.

PMID:
18323547
11.

High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group.

Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT; Late Effects Study Group.

J Clin Oncol. 2003 Dec 1;21(23):4386-94.

PMID:
14645429
12.
13.

Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers.

M'kacher R, Bennaceur-Griscelli A, Girinsky T, Koscielny S, Delhommeau F, Dossou J, Violot D, Leclercq E, Courtier MH, Béron-Gaillard N, Assaf E, Ribrag V, Bourhis J, Feneux D, Bernheim A, Parmentier C, Carde P.

Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):465-71. Epub 2007 Apr 6.

PMID:
17418962
14.

Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.

van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD Jr, Burgers JM, Somers R.

J Natl Cancer Inst. 1995 Oct 18;87(20):1530-7.

PMID:
7563187
15.

Risk, characteristics, and prognosis of breast cancer after Hodgkin's lymphoma.

Veit-Rubin N, Rapiti E, Usel M, Benhamou S, Vinh-Hung V, Vlastos G, Bouchardy C.

Oncologist. 2012;17(6):783-91. doi: 10.1634/theoncologist.2011-0451. Epub 2012 May 15.

16.

Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.

Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S, Lombardo M, Buda G, Lazzaro A, Gobbi PG, Stelitano C, Morabito F, Quarta G, Brugiatelli M.

Haematologica. 2008 Mar;93(3):398-404. doi: 10.3324/haematol.12120. Epub 2008 Feb 11.

17.

Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.

Huang KP, Weinstock MA, Clarke CA, McMillan A, Hoppe RT, Kim YH.

Arch Dermatol. 2007 Jan;143(1):45-50.

PMID:
17224541
18.

Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies.

Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD.

Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):609-16.

PMID:
9336140
19.

Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.

Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E.

J Natl Cancer Inst. 2002 Feb 6;94(3):182-92.

PMID:
11830608
20.

Supplemental Content

Support Center